| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HLA class II histocompatibility antigen, DR alpha chain, MHC class II antigen DRA, HLA-DRA, HLA-DRA1 |
| Entrez GeneID | 3122 |
| WB Predicted band size | 28.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This HLA-DRA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from the N-terminal region of human HLA-DRA. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于HLA-DRA (N-term)抗体的示例参考文献(注：以下内容为模拟生成，非真实文献)：
---
1. **文献名称**: "HLA-DRA N-terminal antibody reveals differential expression in autoimmune thyroiditis"
**作者**: Smith J, et al.
**摘要**: 该研究利用HLA-DRA (N-term)特异性抗体，通过免疫组化分析发现HLA-DRA在桥本甲状腺炎患者甲状腺组织中显著高表达，提示其可能参与自身抗原递呈异常机制。
2. **文献名称**: "Targeting HLA-DRA extracellular domain for cancer immunotherapy screening"
**作者**: Chen L, et al.
**摘要**: 研究开发了一种靶向HLA-DRA N端表位的单克隆抗体，并验证其在流式细胞术和免疫沉淀中的特异性。结果显示，该抗体可识别肿瘤细胞表面HLA-DRA，为免疫检查点疗法提供潜在标记物。
3. **文献名称**: "Structural analysis of HLA-DRA using N-terminal specific antibodies"
**作者**: Müller R, et al.
**摘要**: 通过HLA-DRA (N-term)抗体结合X射线晶体学技术，揭示了HLA-DRA分子N端α链的构象变化，为理解MHC II类分子与T细胞受体相互作用机制提供结构依据。
4. **文献名称**: "HLA-DRA as a biomarker in inflammatory bowel disease"
**作者**: Garcia A, et al.
**摘要**: 采用HLA-DRA (N-term)抗体对结肠活检样本进行Western blot分析，发现克罗恩病患者黏膜中HLA-DRA表达水平与疾病活动度呈正相关，提示其作为炎症监测指标的潜力。
---
**说明**：以上文献为模拟生成，实际引用时需通过PubMed或Google Scholar等数据库检索真实文献。
The HLA-DRA (N-term) antibody targets the N-terminal region of the HLA-DRA protein, a critical component of the major histocompatibility complex class II (MHC II) in humans. HLA-DRA encodes the alpha chain of the HLA-DR heterodimer, which pairs with the beta chain (HLA-DRB) to form a functional antigen-presenting complex. MHC II molecules are primarily expressed on antigen-presenting cells (e.g., dendritic cells, macrophages, and B cells) and play a central role in adaptive immunity by presenting exogenous peptide antigens to CD4+ T cells, initiating immune responses against pathogens and foreign substances.
The HLA-DRA (N-term) antibody is widely used in immunological research to study MHC II expression, trafficking, and function. It helps detect HLA-DR complexes in techniques like Western blotting, immunofluorescence, flow cytometry, and immunohistochemistry. Researchers employ this antibody to investigate dysregulated MHC II expression in autoimmune diseases (e.g., rheumatoid arthritis, type 1 diabetes), infectious diseases, and cancers, where altered antigen presentation may contribute to immune evasion or hyperactivation.
Due to its specificity for the conserved N-terminal epitope, this antibody is valuable in distinguishing HLA-DRA from other MHC II alpha chains (e.g., HLA-DP, HLA-DQ). Its applications extend to characterizing immune cell subsets, monitoring therapeutic responses, and validating HLA-DR-related mechanisms in disease models. Proper validation using knockout controls or peptide-blocking assays is essential to ensure specificity in experimental settings.
×
